EA006684B1 - Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина и ингибиторов топоизомераз i и ii - Google Patents

Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина и ингибиторов топоизомераз i и ii Download PDF

Info

Publication number
EA006684B1
EA006684B1 EA200300060A EA200300060A EA006684B1 EA 006684 B1 EA006684 B1 EA 006684B1 EA 200300060 A EA200300060 A EA 200300060A EA 200300060 A EA200300060 A EA 200300060A EA 006684 B1 EA006684 B1 EA 006684B1
Authority
EA
Eurasian Patent Office
Prior art keywords
topoisomerase
amino
inhibitor
methyl
derivative
Prior art date
Application number
EA200300060A
Other languages
English (en)
Russian (ru)
Other versions
EA200300060A1 (ru
Inventor
Мария Кристина Роза Джерони
Паоло Коцци
Итало Берия
Original Assignee
Фармация Италия С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Италия С.П.А. filed Critical Фармация Италия С.П.А.
Publication of EA200300060A1 publication Critical patent/EA200300060A1/ru
Publication of EA006684B1 publication Critical patent/EA006684B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200300060A 2000-06-23 2001-06-20 Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина и ингибиторов топоизомераз i и ii EA006684B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015444.3A GB0015444D0 (en) 2000-06-23 2000-06-23 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
PCT/EP2001/007059 WO2001097789A2 (en) 2000-06-23 2001-06-20 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors

Publications (2)

Publication Number Publication Date
EA200300060A1 EA200300060A1 (ru) 2003-04-24
EA006684B1 true EA006684B1 (ru) 2006-02-24

Family

ID=9894285

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300060A EA006684B1 (ru) 2000-06-23 2001-06-20 Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина и ингибиторов топоизомераз i и ii

Country Status (27)

Country Link
US (1) US20030162722A1 (enExample)
EP (1) EP1292290B1 (enExample)
JP (1) JP2003535890A (enExample)
KR (1) KR100853955B1 (enExample)
CN (1) CN1241573C (enExample)
AT (1) ATE323483T1 (enExample)
AU (2) AU7846301A (enExample)
BR (1) BR0111813A (enExample)
CA (1) CA2411172C (enExample)
CZ (1) CZ20024155A3 (enExample)
DE (1) DE60118914T2 (enExample)
DK (1) DK1292290T3 (enExample)
EA (1) EA006684B1 (enExample)
EE (1) EE05319B1 (enExample)
ES (1) ES2261448T3 (enExample)
GB (1) GB0015444D0 (enExample)
HK (1) HK1054334B (enExample)
HU (1) HUP0301257A2 (enExample)
IL (1) IL153177A0 (enExample)
MX (1) MXPA02012163A (enExample)
NO (1) NO329783B1 (enExample)
NZ (1) NZ523000A (enExample)
PL (1) PL200503B1 (enExample)
PT (1) PT1292290E (enExample)
SK (1) SK287549B6 (enExample)
WO (1) WO2001097789A2 (enExample)
ZA (1) ZA200209834B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
DE60210329T2 (de) * 2002-01-02 2006-11-30 Nerviano Medical Sciences S.R.L., Nerviano Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren
CN100438913C (zh) * 2004-11-22 2008-12-03 山东蓝金生物工程有限公司 一种抗癌药物组合物
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
CN109718228A (zh) * 2017-10-30 2019-05-07 沈阳药科大学 米托蒽醌的抗肿瘤淋巴转移作用及其药物制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
GB9806692D0 (en) * 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare

Also Published As

Publication number Publication date
ATE323483T1 (de) 2006-05-15
NZ523000A (en) 2005-12-23
MXPA02012163A (es) 2003-04-25
KR100853955B1 (ko) 2008-08-25
NO20026078D0 (no) 2002-12-18
AU7846301A (en) 2002-01-02
CA2411172A1 (en) 2001-12-27
EE200200681A (et) 2004-06-15
US20030162722A1 (en) 2003-08-28
SK18332002A3 (sk) 2003-07-01
HK1054334B (zh) 2006-09-22
WO2001097789A3 (en) 2002-05-16
ZA200209834B (en) 2003-12-04
EA200300060A1 (ru) 2003-04-24
CN1437474A (zh) 2003-08-20
CA2411172C (en) 2009-11-17
HK1054334A1 (en) 2003-11-28
JP2003535890A (ja) 2003-12-02
HUP0301257A2 (hu) 2003-08-28
PT1292290E (pt) 2006-08-31
CN1241573C (zh) 2006-02-15
PL360297A1 (en) 2004-09-06
DE60118914T2 (de) 2006-12-21
WO2001097789A2 (en) 2001-12-27
EP1292290B1 (en) 2006-04-19
IL153177A0 (en) 2003-06-24
PL200503B1 (pl) 2009-01-30
DE60118914D1 (de) 2006-05-24
KR20030019448A (ko) 2003-03-06
AU2001278463B2 (en) 2006-02-23
EE05319B1 (et) 2010-08-16
GB0015444D0 (en) 2000-08-16
EP1292290A2 (en) 2003-03-19
BR0111813A (pt) 2003-05-20
DK1292290T3 (da) 2006-07-10
SK287549B6 (sk) 2011-01-04
ES2261448T3 (es) 2006-11-16
CZ20024155A3 (cs) 2003-04-16
NO329783B1 (no) 2010-12-13
NO20026078L (no) 2002-12-18

Similar Documents

Publication Publication Date Title
KR20010102364A (ko) 상승작용성 항종양 조성물
US6403563B1 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
KR100853955B1 (ko) 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물
AU2001278463A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
AU2002221622B2 (en) Antitumor therapy comprising distamycin derivatives
KR100869037B1 (ko) 치환된 아크릴로일 디스타마이신 유도체 및 알킬화제를 포함하는 항종양 조성물
AU2001281867A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
KR100861668B1 (ko) 치환된 아크릴로일 디스타마이신 유도체, 탁산 및/또는 항대사물질을 포함하는, 항종양 배합 치료제
US20070249651A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
AU2001267553A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
KR20040078118A (ko) 치환된 아크릴로일 디스타마이신 유도체 및 단백질 키나제(세린/트레오닌 키나제) 저해제를 포함하는 항종양 조합요법
HK1060312A (en) Antitumor therapy comprising distamycin derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): BY RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ MD TJ TM RU